« Back
Home /
Lucerastat

Lucerastat

Item no.	HY-106392-25mg
Manufacturer	MedChem Express
CASRN	141206-42-0
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.\|[2]R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.
Smiles	O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	NB-DGJ,N-(n-Butyl)deoxygalactonojirimycin
Similar products	141206-42-0
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	Glucosylceramide Synthase (GCS)
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture)
Molecular Weight	219.28
Product Description	Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].
Manufacturer - Research Area	Metabolic Disease
Solubility	DMSO: 22 mg/mL (ultrasonic; warming; heat to 80°C)\|H2O: 24 mg/mL (ultrasonic; warming; heat to 80°C)
Manufacturer - Pathway	Neuronal Signaling
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-106392-25mg-safety-datasheet.pdf